Twist Bioscience Co. to Post Q1 2025 Earnings of ($0.69) Per Share, William Blair Forecasts (NASDAQ:TWST)

Twist Bioscience Co. (NASDAQ:TWST) – Equities researchers at William Blair boosted their Q1 2025 earnings per share estimates for Twist Bioscience in a research report issued to clients and investors on Monday, June 17th. William Blair analyst M. Larew now forecasts that the company will earn ($0.69) per share for the quarter, up from their prior estimate of ($0.71). The consensus estimate for Twist Bioscience’s current full-year earnings is ($3.08) per share. William Blair also issued estimates for Twist Bioscience’s Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($2.44) EPS.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The business had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. During the same period in the prior year, the business posted ($1.06) earnings per share. The company’s quarterly revenue was up 25.1% compared to the same quarter last year.

Other equities research analysts also recently issued reports about the company. Robert W. Baird upped their price objective on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Barclays upped their price objective on Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd. Guggenheim assumed coverage on Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price target on the stock. Scotiabank increased their price target on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday, May 6th. Finally, Evercore ISI increased their price target on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $46.63.

Twist Bioscience Price Performance

Shares of TWST stock opened at $50.56 on Wednesday. Twist Bioscience has a 1 year low of $14.42 and a 1 year high of $55.26. The stock’s 50 day simple moving average is $41.16 and its two-hundred day simple moving average is $37.26. The company has a market cap of $2.94 billion, a PE ratio of -15.05 and a beta of 1.78.

Institutional Trading of Twist Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its stake in shares of Twist Bioscience by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after buying an additional 427,274 shares during the last quarter. Artisan Partners Limited Partnership lifted its holdings in Twist Bioscience by 111.3% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after acquiring an additional 1,961,621 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Twist Bioscience by 2.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock valued at $132,086,000 after acquiring an additional 99,511 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its holdings in Twist Bioscience by 2.9% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock valued at $131,835,000 after acquiring an additional 99,511 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Twist Bioscience by 29.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock valued at $46,732,000 after acquiring an additional 284,884 shares during the last quarter.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 910 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $33,788.30. Following the sale, the senior vice president now owns 91,511 shares of the company’s stock, valued at approximately $3,397,803.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, COO Patrick John Finn sold 2,174 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total value of $65,480.88. Following the completion of the sale, the chief operating officer now owns 176,206 shares of the company’s stock, valued at approximately $5,307,324.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Paula Green sold 910 shares of Twist Bioscience stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $33,788.30. Following the sale, the senior vice president now directly owns 91,511 shares of the company’s stock, valued at approximately $3,397,803.43. The disclosure for this sale can be found here. Insiders have sold 17,163 shares of company stock worth $666,151 in the last ninety days. 3.92% of the stock is owned by company insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.